Johnson & Johnson Launches Offer for Crucell
As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell — in spite of Crucell’s recent manufacturing troubles.
Continue read…